LSAG
RNAC icon

Lake Street Advisors Group’s Cartesian Therapeutics RNAC Stock Holding History

Lake Street Advisors Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,822
Closed -$255K – 670
2024
Q3 		$255K Sell
15,822
-15,822
-50% -$247K 0.01% 501
2024
Q2 		$855K Buy
+31,644
New +$755K 0.04% 240

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lake Street Advisors Group's RNAC Position: Q4 2024 in Review

Lake Street Advisors Group sold out of Cartesian Therapeutics (RNAC) in Q4 2024, closing a stake of 15,822 shares — an estimated $255K sold.

Lake Street Advisors Group first reported a position in RNAC in Q2 2024 and held it in 2 quarters. The position peaked at $855K in Q2 2024. 68 funds tracked by Wall St. Rank hold RNAC as of Q4 2024.

  • Lake Street Advisors Group reported no remaining Cartesian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lake Street Advisors Group sold 15,822 Cartesian Therapeutics shares in Q4 2024, an estimated $255K.
  • Lake Street Advisors Group first reported a position in Cartesian Therapeutics in Q2 2024 and held it in 2 quarters.
  • Lake Street Advisors Group's Cartesian Therapeutics position peaked at $855K in Q2 2024.
  • 68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2024.

Based on Lake Street Advisors Group's 13F filing for Q4 2024, filed 4 Feb 2025.